APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Legal Investigation - Bragar Eagel & Squire, P C is investigating potential claims against Apellis Pharmaceuticals Inc on behalf of long-term stockholders following a class action complaint filed on August 2 2023 with a Class Period from January 28 2021 to July 28 2023 [2] - The investigation concerns whether the board of directors of Apellis breached their fiduciary duties to the company [2] Allegations - The Complaint alleges that Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Apellis Pharmaceuticals' business and operations during the Class Period [3] - Specifically, Defendants allegedly misrepresented and/or failed to disclose that the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections [3] - As a result, the commercial adoption of SYFOVRE was subject to significant unknown risk factors [3] - Therefore, Defendants' statements about the company's business operations and prospects lacked a reasonable basis [3]